Skeletal muscle marker expression in ossifying fibromyxoid tumor: A study of 44 tumors.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Ossifying fibromyxoid tumor (OFMT) is a rare mesenchymal neoplasm harboring variable malignant potential and showing an immunophenotype classically described as co-expression of desmin and S100. Since its original description, considerable effort has been employed to fully characterize the immunophenotype of OFMT. Prompted by a consultation case of a histologically classic OFMT in which desmin expression was accompanied by expression of the skeletal muscle-specific nuclear regulatory protein MyoD1, we examined the frequency of MyoD1 and myogenin expression in a series of forty four cases of OFMT. Of the 44 cases, MyoD1 expression was present in 23 (52 %) cases, while none were myogenin-positive. MyoD1 expression was found in 20/31 (65 %) desmin-positive tumors, whereas desmin expression was present in 20/23 (87 %) MyoD1-positive tumors. A subset of five cases were stained for PAX7, and a single case of malignant OFMT showed weak expression. To our knowledge, this is the first formal study of rhabdomyoblastic marker expression in OFMT.